Savicell

Savicell is a biotechnology company specializing in the early detection of diseases through its proprietary immunometabolism platform. The company's Well-Shield technology measures the metabolic response of Peripheral Blood Mononuclear Cells (PBMCs) to various stimulants, providing a unique metabolic signature for specific diseases. This approach allows for the non-invasive detection of cancers, such as lung and breast cancer, at very early stages when they are most treatable. By focusing on the immune system's reaction rather than direct tumor markers, Savicell aims to provide higher sensitivity and specificity than traditional liquid biopsy methods. The platform is designed to be rapid, cost-effective, and easily integrated into existing clinical workflows.